Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
22 non » 32 non (Expand Search)
_ step » _ stem (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
22 non » 32 non (Expand Search)
_ step » _ stem (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Aged blood factors decrease cellular responses associated with delayed gingival wound repair
Published 2017“…<div><p>Aging is a gradual biological process characterized by a decrease in cell and organism functions. …”
-
7
-
8
-
9
-
10
-
11
-
12
-
13
Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC.
Published 2025“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”
-
14
-
15
-
16
Non-Pneumatic Anti-Shock Garment (NASG), a First-Aid Device to Decrease Maternal Mortality from Obstetric Hemorrhage: A Cluster Randomized Trial
Published 2013“…<div><p>Background</p><p>Obstetric hemorrhage is the leading cause of maternal mortality. Using a cluster randomized design, we investigated whether application of the Non-pneumatic Anti-Shock Garment (NASG) before transport to referral hospitals (RHs) from primary health care centers (PHCs) decreased adverse outcomes among women with hypovolemic shock. …”
-
17
-
18
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
19
-
20